Previsão

O preço-alvo médio dos analistas é € 15,82 (+67,05%). A mediana é € 12,74 (+34,53%).

Comprar	4
Manter	8
Vender	1

Notícias Ir para o feed de notícias

Eli Lilly reports positive phase 3 trial results with Pirtobrutinib in CLL

Eli Lilly announced that Pirtobrutinib met the primary endpoint and demonstrated a favorable safety profile in a head-to-head phase 3 trial for chronic lymphocytic leukemia (CLL). The company plans to use these results as the basis for global regulatory submissions and also reported regulatory progress for its Alzheimer’s drug Kisunla, as well as the completion of the acquisition of Verve Therapeutics. Analysts remain positive on Eli Lilly, highlighting its strong financial performance. » Mais em de.investing.com
Verve Therapeutics strengthens leadership team with retention bonuses ahead of planned Eli Lilly acquisition

Verve Therapeutics has introduced a retention bonus program for key personnel to secure management ahead of the planned acquisition by Eli Lilly. CFO Allison Dorval and COO Andrew Ashe will receive bonuses contingent on their remaining with the company until the 12th anniversary following the completion of the acquisition. The acquisition agreement offers Verve shareholders $10.50 per share as well as potential additional benefits, while analysts have mixed views on the development. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, VERVE THERAPEUTICS -,001 registou receitas de € 30,48 mi e um ganho líquido de -€ 28,69 mi

(EUR)	março de 2025	YoY
Receitas	30,48 mi	-
Ganho bruto	30,48 mi	-
Ganho líquido	-28,69 mi	-
EBITDA	-32,28 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 873,64 mi
Número de ações	89,31 mi
Máximo/mínimo de 52 semanas	€ 10,02 - € 2,52
Dividendos	Não
Beta	2,24
PER (PE Ratio)	-4,72
PEG (PEG Ratio)	-0,14
P/VC (PB Ratio)	1,91
P/V (PS Ratio)	30,74

Perfil da empresa

Verve Therapeutics, Inc. ist ein Unternehmen für genetische Arzneimittel, das sich mit der Entwicklung von Gen-Editing-Medikamenten für Patienten zur Behandlung von Herz-Kreislauf-Erkrankungen befasst. Der führende Produktkandidat ist VERVE-101, eine einmalige Gene-Editing-Behandlung, die das PCSK9-Gen in der Leber dauerhaft ausschaltet. Das Unternehmen entwickelt auch das ANGPTL3-Programm zur dauerhaften Ausschaltung des ANGPTL3-Gens in der Leber. Es hat eine Kooperations- und Lizenzvereinbarung mit Beam Therapeutics Inc. abgeschlossen, eine Entwicklungs- und Optionsvereinbarung mit Acuitas Therapeutics, Inc. und eine Cas9-Lizenzvereinbarung mit dem Broad Institute und dem President and Fellows of Harvard College. Das Unternehmen war früher als Endcadia, Inc. bekannt und änderte im Januar 2019 seinen Namen in Verve Therapeutics, Inc. Verve Therapeutics, Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	VERVE THERAPEUTICS -,001
CEO	Sekar Kathiresan
Sede	Boston, ma EUA
Site	vervetx.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	17/06/2021
Colaboradores	274